Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment

• Published in: European journal of medical research Vol. 29; no. 1; p. 207
• Main Authors: Ma, Yuan, Li, Jing, Zhao, Xu, Ji, Chao, Hu, Weibin, Ma, YanFang, Qu, Fengyi, Sun, Yuchen, Zhang, Xiaozhi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28.03.2024; BioMed Central; BMC
• Subjects: Algorithms; Analysis; Biomarkers; Cancer; Cancer therapies; Cluster analysis; Clustering; Colorectal cancer; Colorectal Neoplasms - genetics; DNA methylation; Epigenetics; Gene expression; Genes; Humans; Immunotherapy; Medical prognosis; Metastasis; Methylation; MicroRNA; MID2; Molecular subtype; Multi-omics profile; Multiomics; Mutation; Neoplasms; Patients; Polyclonal antibodies; Precision Medicine; Prognosis; Prognostic marker; Regression analysis; Stem cells; Tumor Microenvironment - genetics; China; United States > US; Multi-omics profile; Molecular subtype; MID2; Prognostic marker; Colorectal cancer
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-024-01805-8

Colorectal cancer (CRC) is a complex malignancy characterized by diverse molecular profiles, clinical outcomes, and limited precision in prognostic markers. Addressing these challenges, this study utilized multi-omics data to define consensus molecular subtypes in CRC and elucidate their association with clinical outcomes and underlying biological processes. Consensus molecular subtypes were obtained by applying ten integrated multi-omics clustering algorithms to analyze TCGA-CRC multi-omics data, including mRNA, lncRNA, miRNA, DNA methylation CpG sites, and somatic mutation data. The association of subtypes with prognoses, enrichment functions, immune status, and genomic alterations were further analyzed. Next, we conducted univariate Cox and Lasso regression analyses to investigate the potential prognostic application of biomarkers associated with multi-omics subtypes derived from weighted gene co-expression network analysis (WGCNA). The function of one of the biomarkers MID2 was validated in CRC cell lines. Two CRC subtypes linked to distinct clinical outcomes were identified in TCGA-CRC cohort and validated with three external datasets. The CS1 subtype exhibited a poor prognosis and was characterized by higher tumor-related Hallmark pathway activity and lower metabolism pathway activity. In addition, the CS1 was predicted to have less immunotherapy responder and exhibited more genomic alteration compared to CS2. Then a prognostic model comprising five genes was established, with patients in the high-risk group showing substantial concordance with the CS1 subtype, and those in the low-risk group with the CS2 subtype. The gene MID2, included in the prognostic model, was found to be correlated with epithelial-mesenchymal transition (EMT) pathway and distinct DNA methylation patterns. Knockdown of MID2 in CRC cells resulted in reduced colony formation, migration, and invasion capacities. The integrative multi-omics subtypes proposed potential biomarkers for CRC and provided valuable knowledge for precision oncology.